AIM ImmunoTech Inc (AIM)
AIM ImmunoTech Inc. is a biotechnology company focused on researching and developing therapeutics for cancers, viral diseases, and immune-deficiency disorders in the United States. Its principal products include Ampligen (rintatolimod), a double-stranded RNA-based drug being developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a natural-source alpha interferon product used to treat genital warts. The company is also advancing Ampligen for a range of additional indications, including several cancers, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. Formerly known as Hemispherx Biopharma, Inc., the company adopted the AIM ImmunoTech name in August 2019. Incorporated in 1966, AIM ImmunoTech is headquartered in Ocala, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-AIM
|
$0.33
|
38.8% Upside
|
Undervalued
|
$5.25 2,087.5% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-0.4x
|
2.5x
|
56.4x
|
5.521 M
|
3.995 M
|
45.3%
|
87.5%
|
-94.1
|
—
|
85.2%
|
